Cargando…

Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events

Elevated interleukin-6 (IL-6) levels may correlate with disease severity in COVID-19. We analyzed whether there was an association between elevated IL-6 levels and major adverse cardiac events (MACE) and/or mortality in COVID-19 patients. A retrospective chart review was performed on COVID-19 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Nicholas, Nguyen, Hao, Ukoha, Chijioke, Hoang, Lawrence, Patel, Chirag, Ikram, Farukh G., Acharya, Priyanka, Dhillon, Anmol, Sidhu, Manavjot
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425472/ https://www.ncbi.nlm.nih.gov/pubmed/34966215 http://dx.doi.org/10.1080/08998280.2021.1961571

Ejemplares similares

ELEVATED INTERLEUKIN-6 LEVELS IN COVID-19-INFECTED PATIENTS ARE ASSOCIATED WITH MAJOR ADVERSE CARDIAC EVENTS AND/OR MORTALITY
por: Nguyen, Nicholas, et al.
Publicado: (2021)

TROPONIN-I PREDICTS MAJOR ADVERSE CARDIOVASCULAR EVENTS AND RISK OF MORTALITY IN COVID-19 PATIENTS
por: Patel, Chirag, et al.
Publicado: (2021)

Anticoagulation Use as an Independent Predictor of Mortality and Major Adverse Cardiovascular Events in Hospitalized COVID-19 Patients: A Multicenter Retrospective Analysis
por: DeRon, Nathan, et al.
Publicado: (2023)

Mortality and Major Adverse Cardiovascular Events in Hospitalized Patients With Atrial Fibrillation With COVID-19
por: Wang, Lucas, et al.
Publicado: (2023)

ATRIAL FIBRILLATION AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG HOSPITALIZED COVID-19 PATIENTS
por: Aten, Kristopher, et al.
Publicado: (2022)

BRADYARRHYTHMIAS AND MORTALITY IN COVID-19 PATIENTS
por: Hoang, Lawrence, et al.
Publicado: (2021)

Pulmonary Mucormycosis: An Interesting Case of Rhizopus Mucormycosis
por: Ukoha, Chijioke D, et al.
Publicado: (2021)

EFFECTS OF ELEVATED TROPONIN ON MORTALITY IN HOSPITALIZED COVID-19 PATIENTS WITH AND WITHOUT CORONARY ARTERY DISEASE
por: Zhao, Yi, et al.
Publicado: (2022)

BODY MASS INDEX AS A PREDICTOR OF MORTALITY IN PATIENTS ADMITTED WITH COVID-19, A RETROSPECTIVE STUDY
por: Abualfoul, Mujahed, et al.
Publicado: (2022)

SOCIAL DETERMINANTS OF MORTALITY FROM COVID-19, A RETROSPECTIVE STUDY OF 6,000 PATIENTS
por: Abualfoul, Mujahed, et al.
Publicado: (2022)

AGE AS A PREDICTOR OF MORTALITY IN PATIENTS ADMITTED WITH COVID-19, A RETROSPECTIVE STUDY OF 6,000 PATIENTS
por: Abualfoul, Mujahed, et al.
Publicado: (2022)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events
por: Higgins, Angela Y, et al.
Publicado: (2016)

The burden of major adverse cardiac events in patients with coronary artery disease
por: Tsai, I-Ting, et al.
Publicado: (2017)

Impact of Discrepancies in General and Abdominal Obesity on Major Adverse Cardiac Events
por: Choi, Daein, et al.
Publicado: (2019)

Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus
por: Bruera, Sebastian, et al.
Publicado: (2022)

Major Adverse Cardiac and Cerebrovascular Events in Geriatric Patients with Obstructive Sleep Apnea: An Inpatient Sample Analysis
por: Desai, Rupak, et al.
Publicado: (2023)

Circulating tumor necrosis factor‐α, interleukin‐1β, and interleukin‐17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients
por: Guo, Jing, et al.
Publicado: (2023)

Associations of Modified Healthy Aging Index With Major Adverse Cardiac Events, Major Coronary Events, and Ischemic Heart Disease
por: Huang, Ninghao, et al.
Publicado: (2023)

Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
por: Yasuda, Masakazu, et al.
Publicado: (2016)

Major adverse cardiac events and drug-coated balloon size in coronary interventions
por: Naguib, David, et al.
Publicado: (2018)

Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery
por: Huo, Bright, et al.
Publicado: (2021)

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events
por: Ikebe, So, et al.
Publicado: (2023)

All-Cause Mortality and Incidence of Major Adverse Cardiac Events in Sickle Cell Nephropathy: A Comparative Study
por: Udani, Kunjan, et al.
Publicado: (2021)

The combination of CYP2C19 polymorphism and inflammatory cell ratios in prognosis cardiac adverse events after acute coronary syndrome
por: Hoang Ngo, Toan, et al.
Publicado: (2023)

ACUTE KIDNEY INJURY AS A PREDICTOR OF MORTALITY IN PATIENTS WITH COVID-19
por: CANELA, VICTOR, et al.
Publicado: (2022)

Predictors of major adverse cardiac events following elective stenting of large coronary arteries
por: Aghajani, Hassan, et al.
Publicado: (2018)

Association of Major Adverse Cardiovascular Events in Patients With Stroke and Cardiac Wall Motion Abnormalities
por: Kamran, Saadat, et al.
Publicado: (2021)

Microvascular reactivity as a predictor of major adverse events in patients with on-pump cardiac surgery
por: Cho, Ah-Reum, et al.
Publicado: (2022)

Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation
por: Jung, Richard G, et al.
Publicado: (2022)

Myocardial Injury Is Associated with the Incidence of Major Adverse Cardiac Events in Patients with Severe Trauma
por: Stroda, Alexandra, et al.
Publicado: (2022)

Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
por: Imperiali, Claudia E., et al.
Publicado: (2020)

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions
por: Kallis, Constantinos, et al.
Publicado: (2023)

Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis
por: Kobayashi, Yuta, et al.
Publicado: (2021)

The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
por: Ruge, Max, et al.
Publicado: (2021)

Atrial Fibrillation as a Risk Factor for Major Adverse Cardiac and Cerebrovascular Events after Non-cardiac Surgery
por: Shin, Dong Geum, et al.
Publicado: (2020)

ATRIAL FIBRILLATION AND MORTALITY IN COVID-19 PATIENTS
por: Wang, Lucas, et al.
Publicado: (2022)

Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins
por: Wei, Wei-Qi, et al.
Publicado: (2014)

The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention
por: Safarian, Hadi, et al.
Publicado: (2014)

Manipal lifestyle modification score to predict major adverse cardiac events in postcoronary angioplasty patients
por: Devasia, Tom, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ecpj68adusm8urjfrcmm32gf1b